Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A 0.086-mm 2 12.7-pJ/SOP 64k-Synapse 256-Neuron Online-Learning Digital Spiking Neuromorphic Processor in 28-nm CMOS.

Frenkel C, Lefebvre M, Legat JD, Bol D.

IEEE Trans Biomed Circuits Syst. 2019 Feb;13(1):145-158. doi: 10.1109/TBCAS.2018.2880425. Epub 2018 Nov 9.

PMID:
30418919
2.

A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers.

Hamilton JM, Harding MW, Genna T, Bol DK.

J Clin Pharmacol. 2009 Jan;49(1):30-8. doi: 10.1177/0091270008325149. Epub 2008 Oct 29.

PMID:
18971325
3.

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics.

Kellar KA, Lorenzi MV, Ho CP, You D, Wen ML, Ryseck RP, Oppenheimer S, Fink BE, Vite GD, Rowley BR, Yu C, Bol DK, Lee FY, Wong TW.

Mol Cancer Ther. 2006 Jun;5(6):1571-6.

4.
5.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW.

Cancer Res. 2005 May 1;65(9):3781-7.

6.

Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis.

Feith DJ, Bol DK, Carboni JM, Lynch MJ, Sass-Kuhn S, Shoop PL, Shantz LM.

Cancer Res. 2005 Jan 15;65(2):572-8.

7.

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.

Manne V, Lee FY, Bol DK, Gullo-Brown J, Fairchild CR, Lombardo LJ, Smykla RA, Vite GD, Wen ML, Yu C, Wong TW, Hunt JT.

Cancer Res. 2004 Jun 1;64(11):3974-80. Erratum in: Cancer Res. 2004 Oct 15;64(20):7645.

8.

Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis.

Matsumoto T, Jiang J, Kiguchi K, Ruffino L, Carbajal S, Beltrán L, Bol DK, Rosenberg MP, DiGiovanni J.

Cancer Res. 2003 Aug 15;63(16):4819-28.

9.

Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells.

Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE, Vogel SN.

J Cereb Blood Flow Metab. 2003 Jun;23(6):748-55.

PMID:
12796723
10.

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.

Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR.

J Med Chem. 2002 Aug 29;45(18):3905-27.

PMID:
12190313
11.

Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.

Bol DK, Rowley RB, Ho CP, Pilz B, Dell J, Swerdel M, Kiguchi K, Muga S, Klein R, Fischer SM.

Cancer Res. 2002 May 1;62(9):2516-21.

Supplemental Content

Loading ...
Support Center